Filtered By:
Specialty: Cancer & Oncology
Condition: Coronary Heart Disease
Cancer: Colorectal Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 51 results found since Jan 2013.

Cancers, Vol. 15, Pages 2077: Presence of Multi-Morbidities and Colorectal Cancer Screening Utilization among Breast Cancer Survivors
Conclusion: Among breast cancer survivors, multi-morbidities were positively associated with CRC screening.
Source: Cancers - March 30, 2023 Category: Cancer & Oncology Authors: Meng-Han Tsai Caitlyn Grunert Jacqueline B. Vo Justin X. Moore Avirup Guha Tags: Article Source Type: research

Omega-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality
CONCLUSIONS: Higher concentrations of marine-derived omega-3 PUFA biomarkers were associated with a significantly reduced risk of total CVD, CHD, and total mortality. Levels of ALA were inversely associated with a lower risk of T2D but not CVD-related outcomes. These data support the dietary recommendations advocating the role of omega-3 PUFAs in maintaining an overall lower risk of developing cardiovascular disease and premature deaths.PMID:35830775 | DOI:10.1016/j.clnu.2022.06.034
Source: Clinical Colorectal Cancer - July 13, 2022 Category: Cancer & Oncology Authors: Hong Jiang Lina Wang Duolao Wang Ni Yan Chao Li Min Wu Fan Wang Baibing Mi Fangyao Chen Wanru Jia Xi Liu Jiaxin Lv Yan Liu Jing Lin Le Ma Source Type: research

Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development
Cancer J. 2022 May-Jun 01;28(3):196-203. doi: 10.1097/PPO.0000000000000598.ABSTRACTSeveral formulations of intravaginal oestrogen are available for the treatment of genitourinary syndrome of menopause (GSM). These are safe and effective treatments for the symptoms of GSM. Licensed doses of intravaginal oestrogen do not elevate systemic estradiol levels above the normal postmenopausal range with long term use and there is no evidence of an increased risk of coronary heart disease, stroke, thromboembolism, colorectal cancer, endometrial cancer, breast cancer or breast cancer recurrence with their use. This should reassure bo...
Source: Cancer Journal - May 20, 2022 Category: Cancer & Oncology Authors: Abbie J Laing Louise Newson James A Simon Source Type: research